Views & Analysis Health Innovators: Eliot Forster, F-Star In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star
News Merck KGaA takes second option from cancer immunotherapy pac... Germany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics.
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
Views & Analysis Will the UK ever produce a world-class biotech company? Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.
News Patient organisations 'too influenced by corporate funders' Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.